Compile Data Set for Download or QSAR
Report error Found 435 Enz. Inhib. hit(s) with all data for entry = 9265
TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453719(US10730863, Example 5)
Affinity DataEC50:  71nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453720(US10730863, Example 25)
Affinity DataEC50:  300nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453721(US10730863, Example 26)
Affinity DataEC50:  980nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453722(US10730863, Example 27)
Affinity DataEC50:  26nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453723(US10730863, Example 28)
Affinity DataEC50:  40nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453724(US10730863, Example 29)
Affinity DataEC50:  330nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453725(US10730863, Example 30)
Affinity DataEC50:  37nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453726(US10730863, Example 31)
Affinity DataEC50:  370nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453727(US10730863, Example 32)
Affinity DataEC50:  300nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453728(US10730863, Example 33)
Affinity DataEC50:  170nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453729(US10730863, Example 34)
Affinity DataEC50:  5.10E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453730(US10730863, Example 35)
Affinity DataEC50:  2.40E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453731(US10730863, Example 36)
Affinity DataEC50:  3.50E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453732(US10730863, Example 37)
Affinity DataEC50:  190nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453733(US10730863, Example 38)
Affinity DataEC50:  360nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453734(US10730863, Example 39)
Affinity DataEC50:  140nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453735(US10730863, Example 40 | US10730863, Example 41)
Affinity DataEC50:  100nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453735(US10730863, Example 40 | US10730863, Example 41)
Affinity DataEC50:  470nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453737(US10730863, Example 42)
Affinity DataEC50:  1.50E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453738(US10730863, Example 43)
Affinity DataEC50:  230nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453739(US10730863, Example 44)
Affinity DataEC50:  870nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453740(US10730863, Example 45)
Affinity DataEC50:  490nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453741(US10730863, Example 46)
Affinity DataEC50:  2.70E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453742(US10730863, Example 47)
Affinity DataEC50:  550nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453743(US10730863, Example 48)
Affinity DataEC50:  2.10E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453744(US10730863, Example 49)
Affinity DataEC50:  1.20E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453745(US10730863, Example 50)
Affinity DataEC50:  2.10E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453746(US10730863, Example 51)
Affinity DataEC50:  500nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453747(US10730863, Example 52)
Affinity DataEC50:  170nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453748(US10730863, Example 53)
Affinity DataEC50:  100nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453749(US10730863, Example 54)
Affinity DataEC50:  24nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453750(US10730863, Example 55)
Affinity DataEC50:  250nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453751(US10730863, Example 56)
Affinity DataEC50:  75nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453752(US10730863, Example 57)
Affinity DataEC50:  650nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453753(US10730863, Example 58)
Affinity DataEC50:  4.00E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453754(US10730863, Example 59)
Affinity DataEC50:  3.80E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453755(US10730863, Example 60)
Affinity DataEC50:  220nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453756(US10730863, Example 61)
Affinity DataEC50:  840nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453757(US10730863, Example 62)
Affinity DataEC50:  1.30E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453758(US10730863, Example 73)
Affinity DataEC50:  600nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453759(US10730863, Example 74)
Affinity DataEC50:  520nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453760(US10730863, Example 77 | US10730863, Example 78)
Affinity DataEC50:  180nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453760(US10730863, Example 77 | US10730863, Example 78)
Affinity DataEC50:  1.40E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453762(US10730863, Example 79)
Affinity DataEC50:  130nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453763(US10730863, Example 81)
Affinity DataEC50:  4.70E+3nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453764(US10730863, Example 82)
Affinity DataEC50:  22nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453765(US10730863, Example 83)
Affinity DataEC50:  18nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453766(US10730863, Example 84)
Affinity DataEC50:  320nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453767(US10730863, Example 88)
Affinity DataEC50:  960nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM453768(US10730863, Example 90)
Affinity DataEC50:  11nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 435 total ) | Next | Last >>
Jump to: